Equities Analysts Offer Predictions for Sangamo Therapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:SGMO)

Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) - HC Wainwright issued their Q1 2025 earnings estimates for shares of Sangamo Therapeutics in a research report issued to clients and investors on Wednesday, May 15th. HC Wainwright analyst P. Trucchio expects that the biopharmaceutical company will earn ($0.05) per share for the quarter. HC Wainwright has a "Buy" rating and a $5.00 price objective on the stock. The consensus estimate for Sangamo Therapeutics' current full-year earnings is ($0.54) per share. HC Wainwright also issued estimates for Sangamo Therapeutics' Q2 2025 earnings at ($0.05) EPS, Q3 2025 earnings at ($0.06) EPS, Q4 2025 earnings at $0.06 EPS and FY2028 earnings at $0.19 EPS.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last posted its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.05). Sangamo Therapeutics had a negative net margin of 1,749.06% and a negative return on equity of 182.55%. The company had revenue of $0.48 million for the quarter, compared to the consensus estimate of $8.51 million. During the same quarter last year, the company earned $0.12 earnings per share.

A number of other research analysts also recently issued reports on the stock. StockNews.com initiated coverage on shares of Sangamo Therapeutics in a research report on Saturday, April 27th. They issued a "sell" rating on the stock. Royal Bank of Canada restated a "sector perform" rating and issued a $2.00 price target on shares of Sangamo Therapeutics in a research report on Thursday, March 14th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the company's stock. According to MarketBeat.com, Sangamo Therapeutics currently has an average rating of "Hold" and a consensus price target of $5.67.

Sangamo Therapeutics Stock Performance

Shares of Sangamo Therapeutics stock traded up $0.03 during trading hours on Thursday, reaching $0.61. The company's stock had a trading volume of 2,927,003 shares, compared to its average volume of 2,129,739. The company's 50 day simple moving average is $0.62 and its 200 day simple moving average is $0.59. Sangamo Therapeutics has a one year low of $0.29 and a one year high of $1.67. The stock has a market cap of $126.31 million, a P/E ratio of -0.31 and a beta of 1.40.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. State Board of Administration of Florida Retirement System increased its holdings in shares of Sangamo Therapeutics by 61.1% during the first quarter. State Board of Administration of Florida Retirement System now owns 62,345 shares of the biopharmaceutical company's stock valued at $42,000 after purchasing an additional 23,650 shares during the period. Mackenzie Financial Corp grew its position in Sangamo Therapeutics by 72.4% in the 4th quarter. Mackenzie Financial Corp now owns 73,799 shares of the biopharmaceutical company's stock valued at $40,000 after buying an additional 31,003 shares in the last quarter. Golden State Equity Partners increased its stake in Sangamo Therapeutics by 21.0% during the 4th quarter. Golden State Equity Partners now owns 201,225 shares of the biopharmaceutical company's stock valued at $109,000 after buying an additional 34,960 shares during the period. Vanguard Personalized Indexing Management LLC bought a new stake in shares of Sangamo Therapeutics during the 3rd quarter worth about $26,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Sangamo Therapeutics by 10.2% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 676,189 shares of the biopharmaceutical company's stock worth $406,000 after acquiring an additional 62,465 shares during the period. Institutional investors and hedge funds own 56.93% of the company's stock.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.